Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Wal-Mart, Kimberly-Clark and NIKE

The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Wal-Mart, Kimberly-Clark and NIKE

    AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

    AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

      Lilly: Jardiance Label to Add Cardiovascular Indication

      Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.

        Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical

        Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical

          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

            Achillion, J&J to Initiate Phase IIb Study on HCV Combo

            Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio (simeprevir).

              Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

              Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

                MedTech Industry Stock Outlook - December 2016

                The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.

                  J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

                  Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

                    Stock Market News for November 28, 2016

                      Company News for November 28, 2016

                      Companies in the News are: JNJ,TAC,CTRP,NAVB,CAH

                        The Zacks Analyst Blog Highlights: Johnson & Johnson, Ascena Retail, Financial Sector, Industrials and Health care

                        The Zacks Analyst Blog Highlights: Johnson & Johnson, Ascena Retail, Financial Sector, Industrials and Health care

                          David Bartosiak headshot

                          Trump Rotation Stocks to Buy Right Now

                          The Trump Rotation has seen money flow into financials, healthcare and industrials but the opportunity is in retail

                            Stock Market News for November 08, 2016

                            Benchmarks ended higher on Monday after the FBI said that it would not press criminal charges against Democratic nominee Hillary Clinton

                              The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Facebook and Qualcomm

                              The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Facebook and Qualcomm

                                Mark Vickery headshot

                                Big Q3 Earnings Checklist, Plus Latest CPI

                                We've got plenty of notable stocks reporting before the bell today, including many large financial institutions on Wall Street.

                                  6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings

                                  A number of healthcare companies are recording improvements in their financial numbers.

                                    Sheraz Mian headshot

                                    A Whole Lot of Nothing

                                    Stocks haven't done much lately and the trend will likely continue for some time.

                                      Sheraz Mian headshot

                                      Is the Earnings Picture Improving?

                                      There are some tell-tale signs of improvement in the aggregate earnings picture.

                                        Sheraz Mian headshot

                                        Is the Earnings Picture Improving?

                                        There are some tell-tale signs of improvement in the aggregate earnings picture.

                                          Stock Market News for July 20, 2016

                                          The Dow ended in the green for the eighth consecutive session on Tuesday following Johnson & Johnson's commendable quarterly performance

                                            MedTech Industry Stock Outlook - July 2016

                                            Two full quarters of 2016 are behind us and, while we await second quarter results over the coming weeks, we hardly expect a change in trend in the bullish MedTech sector.

                                              Stock Market News for June 03, 2016

                                              Benchmarks finished in the green on Thursday following encouraging U.S. private sector jobs data and gains in healthcare stocks

                                                Jeremy Mullin headshot

                                                Hedge Funds Are Buying These Stocks, Should You?

                                                Following the smart money can lead to big gains.

                                                  Kevin Cook headshot

                                                  Bear of the Day: AbbVie (ABBV)

                                                  Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus